Immune microenvironment alteration is one of the main hallmarks of cancer. The immunogenomic feature has been analysed in particular cancer or across diverse cancer types. Multiple modulators are involved in tumour-immune cell interaction, including genetic variations, transcription factors, non-coding RNAs, translational and post-translational modifications, etc. The heterogeneity of the immune microenvironment is marked correlated with the initiation and progression of cancer. It is noteworthy that the application of high-throughput approaches combined with multi-omics data makes it possible to characterise the immune microenvironment's role in cancer comprehensively.
Radiotherapy, chemotherapy, target therapy, and immunotherapy are frequently used treatments for cancer. However, some patients do not receive a response to these therapies. Resistance is still a significant challenge in cancer treatment. The immune microenvironment features exhibited high accuracy in predicting prognosis and therapy responses of cancer patients. A better understanding of the crosstalk and modulator between cancer and immune cells would promote individualised therapy for cancer patients.
The following topics are welcome but not limited to:
• Changes of immune cells in tumor radiotherapy, chemotherapy, target therapy and immunotherapy;
• Gene mutations regulating immunity cells in tumor radiotherapy, chemotherapy, target therapy and immunotherapy;
• Abnormal gene expression/proteins regulating immunity cells in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• Multi-omics data and imaging omics analysis regulating immunity in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• New clinical trials or studies in the regulation of immune cells in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• The changing of cell state regulated by the immune cell in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
Immune microenvironment alteration is one of the main hallmarks of cancer. The immunogenomic feature has been analysed in particular cancer or across diverse cancer types. Multiple modulators are involved in tumour-immune cell interaction, including genetic variations, transcription factors, non-coding RNAs, translational and post-translational modifications, etc. The heterogeneity of the immune microenvironment is marked correlated with the initiation and progression of cancer. It is noteworthy that the application of high-throughput approaches combined with multi-omics data makes it possible to characterise the immune microenvironment's role in cancer comprehensively.
Radiotherapy, chemotherapy, target therapy, and immunotherapy are frequently used treatments for cancer. However, some patients do not receive a response to these therapies. Resistance is still a significant challenge in cancer treatment. The immune microenvironment features exhibited high accuracy in predicting prognosis and therapy responses of cancer patients. A better understanding of the crosstalk and modulator between cancer and immune cells would promote individualised therapy for cancer patients.
The following topics are welcome but not limited to:
• Changes of immune cells in tumor radiotherapy, chemotherapy, target therapy and immunotherapy;
• Gene mutations regulating immunity cells in tumor radiotherapy, chemotherapy, target therapy and immunotherapy;
• Abnormal gene expression/proteins regulating immunity cells in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• Multi-omics data and imaging omics analysis regulating immunity in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• New clinical trials or studies in the regulation of immune cells in tumor radiotherapy, chemotherapy, targeting and immunotherapy;
• The changing of cell state regulated by the immune cell in tumor radiotherapy, chemotherapy, targeting and immunotherapy;